# Atopic Dermatitis (Eczema): Skincare, Medications, and Modern Biologics

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense itching, dryness, and recurring rashes. It is the most common dermatosis: affecting up to 20% of children and 2–10% of adults worldwide. AD significantly impacts quality of life — disrupting sleep, social activity, and mental health. The good news: proper basic skincare + stepwise therapy controls the disease in the vast majority of patients.

AD is not simply "skin allergy." Two interconnected defects underlie it: Skin barrier dysfunction — 30–50% of patients carry a filaggrin gene mutation (key protein that "glues" together keratinocytes). Result: skin loses moisture, becomes easily permeable to allergens and microbes. Immune dysregulation — Th2-dominant response → excessive IL-4, IL-13, IL-31 (the "itch cytokine") production. Th2 inflammation perpetuates a vicious cycle: weakened barrier → antigens penetrate → inflammation → barrier weakens further.

Understanding the role of IL-4/IL-13 led to the creation of dupilumab — a breakthrough biologic.

Infants (0–2 years): cheeks, forehead, extensor surfaces affected. Weeping, crusting. Children (2–12 years): typical flexural distribution (antecubital and popliteal fossae), neck, wrists. Lichenification (skin thickening from chronic scratching). Adults: face, neck, hands, flexural surfaces. Marked dryness and lichenification. 30% have comorbid allergic diseases (asthma, allergic rhinitis) — the "atopic march."

Severity assessment: SCORAD, EASI — standardized indices. Mild — isolated patches, moderate itch. Moderate — widespread lesions, significant itch, sleep disruption. Severe — generalized involvement, incessant itch, major QoL impairment.

Emollients (moisturizers) are the most important therapy component at every stage. They restore the skin barrier and reduce the need for anti-inflammatory agents.

Rules: apply MINIMUM twice daily to ALL skin (not just affected areas); quantity — at least 250 g/week for adults; apply immediately after bathing (within 3 minutes on damp skin); fragrance-free, dye-free, preservative-free. Forms: creams — for weeping lesions; ointments — for dry, lichenified skin (better moisture retention); lotions — for hairy areas.

Bathing: daily, 5–10 minutes, warm (not hot!) water, mild soap-free cleansers (syndets). Avoid soap — it destroys the lipid mantle.

Emollients only. If insufficient — proceed to step 2.

Topical corticosteroids (TCS) are the backbone of anti-inflammatory therapy during flares.

[Hydrocortisone](/search?q=hydrocortisone) 1% — mild TCS. For face, skin folds, infants. [Mometasone](/search?q=mometasone) 0.1% cream/ointment — moderate-potency TCS. For trunk and extremities. Once daily (convenient). Fingertip unit (FTU) rule — the amount of cream squeezed onto one fingertip = dose for treating an area equal to two palms.

Regimens: reactive — apply during flare until clear (usually 7–14 days); proactive — after flare resolution, apply twice weekly to "problem zones" to prevent relapse. Proactive regimen is a proven strategy for reducing flares.

Steroid myths: "corticosteroid phobia" is a leading cause of treatment failure. Topical corticosteroids are safe when used correctly. Side effects (atrophy, telangiectasia) develop with prolonged CONTINUOUS use of potent TCS, not with short courses.

[Tacrolimus](/search?q=tacrolimus) 0.03%/0.1% ointment — for face, folds, long-term use (doesn't cause skin atrophy). 0.1% efficacy comparable to moderate-potency TCS. [Pimecrolimus](/search?q=pimecrolimus) 1% cream — weaker than tacrolimus, for mild forms and sensitive areas.

Side effect: burning sensation on initial application (resolves in 3–5 days). Tip: start with small areas, apply after emollient. Ideal for proactive therapy on face and folds.

Phototherapy (UVB 311 nm) — proven efficacy in widespread AD. 2–3 times/week, 20–30 session course.

[Cyclosporine](/search?q=cyclosporine) 3–5 mg/kg/day — rapid effect (2–4 weeks). For crisis management of severe flares. Limitations: nephrotoxicity (creatinine monitoring), hypertension, immunosuppression. Course: usually ≤1 year. [Methotrexate](/search?q=methotrexate) 10–15 mg/week — for longer-term therapy. Slower onset (8–12 weeks) but well tolerated. Folic acid mandatory.

[Crisaborole](/search?q=crisaborole) 2% ointment — PDE-4 inhibitor. Non-steroidal anti-inflammatory for mild-moderate AD. Alternative to TCS and calcineurin inhibitors.

[Dupilumab](/search?q=dupilumab) — monoclonal antibody blocking IL-4 and IL-13. A breakthrough in severe AD treatment.

Regimen: 600 mg (loading dose) → 300 mg subcutaneous every 2 weeks. Efficacy: 70–80% of patients achieve significant improvement (EASI-75). Itch decreases within 1–2 weeks. Side effects: conjunctivitis (10–20% — most common), injection site reactions. Excellent overall safety profile — no blood monitoring required. Approved for adults and children from age 6 (in some countries from 6 months).

JAK inhibitors (next generation): baricitinib, upadacitinib, abrocitinib — oral tablets. Rapid onset (1–2 weeks). Efficacy comparable to dupilumab. Side effects: infections, thrombosis (FDA warnings), cholesterol elevation.

AD itch is tormenting, disrupts sleep, causes scratching and secondary infection. Strategies: Emollients — reduce dryness (the primary itch trigger). Anti-inflammatory therapy — eliminating inflammation = eliminating itch (TCS, TCI, dupilumab). [Cetirizine](/search?q=cetirizine) 10 mg/day — antihistamine. Honestly: ineffective against AD itch (AD itch is not histamine-mediated). May help with sleep (sedative effect in some). Wet wraps — for severe flares: wet bandage over emollient or diluted TCS → dry bandage → for 2–4 hours. Rapidly reduces itch and inflammation.

AD skin is colonized by Staphylococcus aureus in 90% of patients. Impetiginization — crusting, weeping, yellow deposits → systemic antibiotics (flucloxacillin, cephalexin). Antiseptic baths (chlorhexidine, diluted bleach — "bleach baths") twice weekly — proven to reduce colonization. Eczema herpeticum (Kaposi varicelliform eruption) — disseminated herpes on AD skin. Emergency! Treatment: IV acyclovir. Temporarily discontinue topical corticosteroids.

Food allergens — confirmed in only 30% of children with severe AD (cow's milk, eggs, peanuts). Elimination diets — only after confirmation with provocation testing, not "just in case." Contact irritants — synthetic clothing, wool, household chemicals. Wear cotton or silk. Aeroallergens — dust mites, pollen, pet dander. Stress — proven flare trigger. Climate — cold dry air worsens AD, warm humid air improves it.

60–70% of children with AD "outgrow" the disease by adolescence. But 30–40% continue into adulthood. Poor prognostic factors: early onset, severe course, filaggrin mutation, multiple atopy. Modern therapy (especially biologics) has dramatically improved outcomes for patients with severe forms.

*This article is for informational purposes only and does not replace medical advice. Consult a dermatologist before starting or changing treatment.*